277 related articles for article (PubMed ID: 9827976)
1. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial.
Karthaus M; Rosenthal C; Huebner G; Paul H; Elser C; Hertenstein B; Krauter J; Scharmann T; Geissler RG; Heil G; Ganser A
Bone Marrow Transplant; 1998 Oct; 22(8):781-5. PubMed ID: 9827976
[TBL] [Abstract][Full Text] [Related]
2. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.
Crawford J; Tomita DK; Mazanet R; Glaspy J; Ozer H
Cytokines Cell Mol Ther; 1999 Dec; 5(4):187-93. PubMed ID: 10850381
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
[TBL] [Abstract][Full Text] [Related]
4. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study.
Valcárcel D; Sanz MA; Sureda A; Sala M; Muñoz L; Subirá M; Laborda R; Clopés A; Sierra J
Bone Marrow Transplant; 2002 May; 29(9):783-7. PubMed ID: 12040477
[TBL] [Abstract][Full Text] [Related]
5. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis - are there new strategies?
Karthaus M; Rosenthal C; Ganser A
Bone Marrow Transplant; 1999 Nov; 24(10):1095-108. PubMed ID: 10578160
[TBL] [Abstract][Full Text] [Related]
7. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
9. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Hofmann WK; Seipelt G; Langenhan S; Reutzel R; Schott D; Schoeffski O; Illiger HJ; Hartmann F; Balleisen L; Franke A; Fiedler F; Huber C; Rasche H; Bergmann L; Ganser A; Pott C; Pasold R; Rudolph C; Ottmann OG; Gökbuget N; Hoelzer D
Ann Hematol; 2002 Oct; 81(10):570-4. PubMed ID: 12424538
[TBL] [Abstract][Full Text] [Related]
11. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
13. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)--results of a prospective randomised monocentre study.
Bönig H; Silbermann S; Weller S; Kirschke R; Körholz D; Janssen G; Göbel U; Nürnberger W
Bone Marrow Transplant; 2001 Aug; 28(3):259-64. PubMed ID: 11535993
[TBL] [Abstract][Full Text] [Related]
14. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy.
Peterson DE; Jones JB; Petit RG
Cancer; 2007 Jan; 109(2):322-31. PubMed ID: 17154160
[TBL] [Abstract][Full Text] [Related]
15. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N;
Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926
[TBL] [Abstract][Full Text] [Related]
16. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
[TBL] [Abstract][Full Text] [Related]
17. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
18. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.
Veness MJ; Foroudi F; Gebski V; Timms I; Sathiyaseelan Y; Cakir B; Tiver KW
Australas Radiol; 2006 Oct; 50(5):468-74. PubMed ID: 16981945
[TBL] [Abstract][Full Text] [Related]
19. Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: an interim look at a randomized, double-blind, placebo-controlled trial.
Schneider SB; Nishimura RD; Zimmerman RP; Tran L; Shiplacoff J; Tormey M; Contreras R; Juillard GF
Cytokines Cell Mol Ther; 1999 Sep; 5(3):175-80. PubMed ID: 10641576
[TBL] [Abstract][Full Text] [Related]
20. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
Vadhan-Raj S; Trent J; Patel S; Zhou X; Johnson MM; Araujo D; Ludwig JA; O'Roark S; Gillenwater AM; Bueso-Ramos C; El-Naggar AK; Benjamin RS
Ann Intern Med; 2010 Sep; 153(6):358-67. PubMed ID: 20855800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
